The emergence of GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — has been described as the most significant pharmacological advance in obesity medicine since the field began. These drugs have produced 15% to 22% body weight reductions in clinical trials, achieving results that previously required bariatric surgery, with a mechanism that treats obesity as the metabolic and neurological disease it is, rather than a failure of willpower.
But a new commentary published in Gastroenterology — the journal of the American Gastroenterological Association — and reported by ScienceDaily on June 20, 2026, argues that the current GLP-1 era, as transformative as it has been, is only the opening act. Specialists now envision a future where medications, minimally invasive procedures, bariatric surgery, and precision medicine work together in personalized combinations to deliver better, longer-lasting results than any single approach can achieve alone.
